射血分数保留的心力衰竭中左室舒张充盈主动与被动成分与运动不耐受的关联:螺内酯反应的机制性发现
研究纳入194例射血分数保留的心力衰竭患者,评估左室解旋率与E/e'比值和运动能力的关联,其中105例运动诱导左室充盈压升高者随机接受螺内酯25 mg(n=51)或安慰剂(n=54)治疗6个月。基线峰值耗氧量与解旋率和E/e'均独立相关,治疗后峰值耗氧量改善与两指标变化独立相关;螺内酯对峰值耗氧量的交互作用仅见于E/e'(p=0.02),未见了解旋率(p=0.62)。
要点
- 左室舒张充盈的主动成分(解旋率)和被动成分(E/e')均与射血分数保留的心力衰竭患者运动能力降低相关。
- 螺内酯治疗6个月后功能能力改善与解旋率和E/e'的改善均相关,但药物可能的介导效应仅见于E/e'。
- E/e'与螺内酯对峰值耗氧量存在显著交互作用(p=0.02),解旋率无显著交互作用(p=0.62)。
核心结论
- 左室充盈的主动与被动决定因素(分别以解旋率和E/e'反映)均参与射血分数保留的心力衰竭运动能力降低;螺内酯治疗6个月功能能力改善与两指标改善相关,但药物可能的介导效应仅见于E/e'。
研究设计与样本
- 研究纳入194例射血分数保留的心力衰竭患者(64±8岁),完成包括心肌形变和旋转力学评估的完整超声心动图及最大运动后超声心动图;其中105例运动诱导估测左室充盈压升高者随机接受螺内酯25 mg(n=51)或安慰剂(n=54)治疗6个月。
诊断标准与关键数值
- 基线峰值耗氧量与解旋率独立相关(β=0.19;p=0.01),与E/e'独立相关(β=-0.16;p=0.03),独立于临床资料及纵向形变和心室-动脉耦联的运动储备。
- 治疗前后峰值耗氧量增加与解旋率变化独立相关(β=0.28;p=0.003),与E/e'的运动性增加独立相关(β=-0.23;p=0.01)。
- 螺内酯对峰值耗氧量的交互作用在E/e'中显著(p=0.02),在解旋率中不显著(p=0.62)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to investigate the association of left ventricular (LV) untwisting rate (UT) and E/e' ratio with the response of exercise capacity to spironolactone in heart failure with preserved ejection fraction (HFpEF).
BACKGROUND: In most patients with HFpEF, LV filling abnormalities represent a central component in the development of dyspnea. LV diastolic filling is determined by the interplay of passive (LV stiffness and myocardial collagen content, reflected by E/e' ratio) and active myocardial properties (UT, a precursor to isovolumic pressure decay and contributor to diastolic suction).
METHODS: In 194 patients with HFpEF (64 ± 8 years), a complete echocardiogram (including assessment of myocardial deformation and rotational mechanics) was performed. Echocardiography following maximal exercise was undertaken to assess LV systolic and diastolic responses to stress. A subset of 105 patients with an exercise-induced increase in estimated LV filling pressure were randomly assigned to spironolactone 25 mg (n = 51) or placebo (n = 54) for 6 months.
RESULTS: Baseline peak Vo2 was associated with UT (β = 0.19; p = 0.01) and E/e' (β = -0.16; p = 0.03), independent of clinical data and exercise reserve in longitudinal deformation and ventricular-arterial coupling. An increase in peak Vo2 with treatment was independently associated with changes in UT (β = 0.28; p = 0.003) and exertional increase in E/e' (β = -0.23; p = 0.01) from baseline to follow-up. A significant interaction with the use of spironolactone on peak Vo2 was found for E/e' (p = 0.02) but not for UT (p = 0.62).
CONCLUSIONS: Both active and passive determinants of LV filling, as reflected by UT and E/e', contribute to reduced exercise capacity in HFpEF. Improvement in functional capacity with a 6-month therapy with spironolactone is associated with improvements in both indices. However, the possible mediating effect of this medication is observed only on E/e'.
引用
- Kosmala W, Przewlocka-Kosmala M, Marwick TH, et al. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response. JACC Cardiovasc Imaging. 2017. PMID: 29248640. doi:10.1016/j.jcmg.2017.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。